Cancers & treatments·Regimen libraryFirst line

Imatinib

Checked 2026-09-09

Chronic-phase CML; adjuvant GIST for 3 years after resection of high-risk tumours; metastatic GIST

One cycle

every 28 days

28-day cycle, indefinite (CML; treatment-free remission in deep response); 3 years adjuvant GISTOral Daily oral course

Components

Drug	Dose	Route	Days	Note
Imatinib Small-molecule kinase inhibitor (BCR-ABL, KIT, PDGFRA)	400 mg once daily with food (600-800 mg for KIT exon 9 GIST or accelerated phase)	Oral	D1-28

Cycles

indefinite (CML; treatment-free remission in deep response); 3 years adjuvant GIST

28-day cycle

Emetogenicity

Minimal (<10%)

G-CSF

Not routine

Used in

Chronic myeloid leukaemia (CML)Gastrointestinal stromal tumour (GIST)Acute lymphoblastic leukaemia

Trials

SSGXVIII/AIO (adjuvant imatinib in GIST)

Products

Imatinib

Source

IRIS, NEJM 2003; SSGXVIII/AIO, JAMA 2012

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.